Mcl-1-Puma inhibitor 8

CAS No. 678158-55-9

Mcl-1-Puma inhibitor 8( Mcl-1-PUMA modulator-8 )

Catalog No. M15591 CAS No. 678158-55-9

Mcl-1-Puma inhibitor 8 is a small-molecule dual-acting compound that targets the apoptotic Mcl-1-PUMA interface with Ki of 0.3 uM (Mcl-1, FPA).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 343 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Mcl-1-Puma inhibitor 8
  • Note
    Research use only, not for human use.
  • Brief Description
    Mcl-1-Puma inhibitor 8 is a small-molecule dual-acting compound that targets the apoptotic Mcl-1-PUMA interface with Ki of 0.3 uM (Mcl-1, FPA).
  • Description
    Mcl-1-Puma inhibitor 8 is a small-molecule dual-acting compound that targets the apoptotic Mcl-1-PUMA interface with Ki of 0.3 uM (Mcl-1, FPA), reduces multiple cancer cells and inhibits PUMA-mediated apoptosis; a useful chemical probe to achieve safer cancer therapies by modulating Mcl-1-PUMA interaction.
  • In Vitro
    CLZ-8 (Compound 8) (0-160 μM, 48 h) significantly inhibits PUMA-dependent apoptosis.CLZ-8 (0-1 μM, 2 h) significantly enhance the irradiated cell viability in a dose-dependent manner, provides significant protection for HUVECs, and inhibits overexpressed PUMA.CLZ-8 (0-1 μM, 24 h) attenuates the radiation-induced apoptosis.CLZ-8 (1 μM, 2 h) protects HUVECs from DNA breaks. Apoptosis Analysis Cell Line:DLD-1 cells or HUVEC cellsConcentration:0-160 μM (DLD-1) or 0.01, 0.1 and 1 μM (HUVECs)Incubation Time:48 h (DLD-1) or 24 h (HUVECs)Result:Significantly inhibited PUMA-dependent apoptosis with an IC50 of 38.93 ± 0.91 μM. Attenuated the radiation-induced apoptosis.Western Blot Analysis Cell Line:HUVEC cells Concentration:0.001, 0.01, 0.1 and 1 μM Incubation Time:2 h Result:Suppressed induction of PUMA after radiation, significantly decreased the level of p53. Significantly decreased the level of MCL-1 and increased the level of Bcl-XL.
  • In Vivo
    CLZ-8 (0-400 mg/kg; i.g.; once) shows powerful anti-radiation effects in mice. Animal Model:6-8 week-old male BALB/c mice Dosage:100, 200 and 400 mg/kg Administration:Intragastric administration, once, 30 min prior to irradiation Result:Increased the survival rate of irradiated mice.
  • Synonyms
    Mcl-1-PUMA modulator-8
  • Pathway
    Angiogenesis
  • Target
    Bcl-2
  • Recptor
    Bcl-2
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    678158-55-9
  • Formula Weight
    393.505
  • Molecular Formula
    C22H23N3O2S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (127.06 mM)
  • SMILES
    O=C1N=C(N2CCN(CCO)CC2)S/C1=C\C3=CC=C(C4=CC=CC=C4)C=C3
  • Chemical Name
    5-([1,1'-biphenyl]-4-ylmethylene)-2-(4-(2-hydroxyethyl)piperazin-1-yl)thiazol-4(5H)-one

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Liu J, et al. Oncotarget. 2017 Apr 20;8(33):54236-54242.
molnova catalog
related products
  • MCL-1/BCL-2-IN-2

    MCL-1/BCL-2-IN-2 is a potent and selective dual inhibitor of Bcl-2 and Mcl-1.

  • MIK665

    MIK665 (S-64315, MIK-665) is a novel potent, selective Mcl-1 inhibitor with potential pro-apoptotic and antineoplastic activities.

  • AT101

    AT-101 is the levorotatory isomer of a natural product Gossypol.